focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.42
Bid: 2.33
Ask: 2.48
Change: 0.155 (6.89%)
Spread: 0.15 (6.438%)
Open: 2.26
High: 2.48
Low: 2.26
Prev. Close: 2.25
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: ScotGold drops two-thirds as gold grade declines

Mon, 27th Mar 2023 10:51

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

ImmuPharma PLC, up 17% at 2.13 pence, 12-month range 1.36p-9.5p. The drug discovery and development company submits a phase 2/3 clinical trial protocol to the US Food & Drug Administration testing the Lupuzor treatment for lupus patients. The new design takes into account the FDA's key guidance points from a previous 'Type C' meeting alongside insights from its pharmacokinetic study completed last year. A Type C meeting with the FDA has been requested, and the company will update the market with the date of the meeting once confirmed by FDA, ImmuPharma says.

----------

Pressure Technologies PLC, up 9.5% at 46p, 12-month range 23p-103p. The specialist engineering group said its subsidiary AI-Met, a part of the Precision Machined Components division, won a GBP3 million order from a "established international [original equipment manufacturer] customer". The company says the order is "unprecedented" and will provide "substantial order book coverage and visibility" for the first half of financial 2023. CEO Chris Walters says he is "delighted" with the order, and it underpins the company's expectations for the full year, including returning to profit at the end of this quarter. Less positively, the firm says it will miss the deadline for publishing its annual results, and will suspend its shares from trading next Monday. Expects suspension to be lifted upon publishing of the results, which will be "no later than the end of April".

----------

AIM - LOSERS

----------

Scotgold Resources Ltd, down 66% at 13.1p, 12-month range 13p-87p. The Scottish gold producer says gold grades at 430 West ore drive declined "significantly" in late February and early March, reducing total ore production. "The 430 West ore drive turned to waste, contradicting the grade control model," ScotGold says. Warns of a "material uncertainty" that could exist if the commencement of long hole stope mining is delayed and ore mining continues to be below the mine plan. In order to strengthen its cash position, Scotgold is discussing a USD500,000 advance with its gold offtake partner to assist with short-term working capital. The directors are also mulling a short-term convertible loan.

----------

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
22 Sep 2020 21:17

IN BRIEF: Immupharma Repays Lind Global Convertible Security

IN BRIEF: Immupharma Repays Lind Global Convertible Security

Read more
11 Sep 2020 14:09

IN BRIEF: Immupharma Still Awaiting FDA Reply For Lupuzor Submission

IN BRIEF: Immupharma Still Awaiting FDA Reply For Lupuzor Submission

Read more
11 Sep 2020 12:17

ImmuPharma confirms continued FDA delays for Lupuzor

(Sharecast News) - Specialist drug discovery and development company ImmuPharma on its special protocol assessment (SPA) submission to the US Food and Drug Administration (FDA) for the phase 3 trial of 'Lupuzor' in lupus patients.

Read more
2 Sep 2020 11:18

Immupharma Raises GBP6.5 Million In Oversubscribed Placing

Immupharma Raises GBP6.5 Million In Oversubscribed Placing

Read more
2 Sep 2020 09:25

Immupharma raises £6.5m in oversubscribed placing

(Sharecast News) - Drug discovery and development firm Immupharma has raised £6.5m, before fees, via an oversubscribed placing of 59.09m ordinary shares.

Read more
27 Jul 2020 17:50

IN BRIEF: ImmuPharma Partner Avion Submits Request To FDA For Lupuzor

IN BRIEF: ImmuPharma Partner Avion Submits Request To FDA For Lupuzor

Read more
27 Jul 2020 15:15

ImmuPharma clears 'important' regulatory hurdle for Lupuzor trial

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced what it called "an important regulatory milestone" on Monday, in preparation for the new optimised international phase 3 trial of 'Lupuzor' for the autoimmune disease systemic lupus erythematosus.

Read more
11 Jun 2020 16:17

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
11 Jun 2020 13:53

Immupharma Gets Over USD6 Million Investment From US Healthcare Funds

Immupharma Gets Over USD6 Million Investment From US Healthcare Funds

Read more
14 May 2020 17:13

UK TRADING UPDATE SUMMARY: Byotrol Sees Continuation Of Strong Demand

UK TRADING UPDATE SUMMARY: Byotrol Sees Continuation Of Strong Demand

Read more
1 May 2020 09:51

ImmuPharma Annual Loss Narrows; Plans "Optimised" Lupuzor Trial

ImmuPharma Annual Loss Narrows; Plans "Optimised" Lupuzor Trial

Read more
31 Mar 2020 07:31

ImmuPharma Raises GBP1.5 Million Through Share Issue To Fund Expansion

ImmuPharma Raises GBP1.5 Million Through Share Issue To Fund Expansion

Read more
30 Mar 2020 16:18

ImmuPharma raises ?1.5m to fund development programmes

(Sharecast News) - Drug discovery and development company ImmuPharma announced subscriptions to raise ?1.5m through the issue of 15 million new ordinary shares at a price of 10p each on Monday.

Read more
28 Feb 2020 12:06

Immupharma Inks Subscription Agreement Amid Incanthera's NEX Float

Immupharma Inks Subscription Agreement Amid Incanthera's NEX Float

Read more
6 Feb 2020 15:54

ImmuPharma and Avion to proceed with Lupuzor phase 3 trial

(Sharecast News) - Specialist drug discovery and development company ImmuPharma updated the market on its activities with Avion Pharmaceuticals on Thursday, following the licence and development agreement it signed with Avion in November for the exclusive rights to 'Lupuzor' in North America.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.